| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Taxes paid related to net share settlement of equity awards | 0 | 0 |
| Net cash provided by financing activities | 50,184 | 184 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 17,873 | -6,899 |
| Cash and cash equivalents at beginning of period | 107,287 | - |
| Cash and cash equivalents at end of period | 125,160 | - |
Lyell Immunopharma, Inc. (LYEL)
Lyell Immunopharma, Inc. (LYEL)